A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
Cannabidiol (CBD) is an abundant non‐psychoactive phytocannabinoid in cannabis extracts which has high affinity on a series of receptors, including Type 1 cannabinoid receptor (CB1), Type 2 cannabinoid receptor (CB2), GPR55, transient receptor potential vanilloid (TRPV) and peroxisome proliferator‐a...
Gespeichert in:
| Veröffentlicht in: | Basic & clinical pharmacology & toxicology 2022-04, Vol.130 (4), p.439-456 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 456 |
|---|---|
| container_issue | 4 |
| container_start_page | 439 |
| container_title | Basic & clinical pharmacology & toxicology |
| container_volume | 130 |
| creator | Peng, Jiangling Fan, Mingjie An, Chelsea Ni, Feng Huang, Wendong Luo, Jiankang |
| description | Cannabidiol (CBD) is an abundant non‐psychoactive phytocannabinoid in cannabis extracts which has high affinity on a series of receptors, including Type 1 cannabinoid receptor (CB1), Type 2 cannabinoid receptor (CB2), GPR55, transient receptor potential vanilloid (TRPV) and peroxisome proliferator‐activated receptor gamma (PPARγ). By modulating the activities of these receptors, CBD exhibits multiple therapeutic effects, including neuroprotective, antiepileptic, anxiolytic, antipsychotic, anti‐inflammatory, analgesic and anticancer properties. CBD could also be applied to treat or prevent COVID‐19 and its complications. Here, we provide a narrative review of CBD's applications in human diseases: from mechanism of action to clinical trials. |
| doi_str_mv | 10.1111/bcpt.13710 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2623329050</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2638058563</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4590-10ba9d3afae734ca40333d8f93d07f51e325e49ed1df5d52c6e52a1d7c8ffe623</originalsourceid><addsrcrecordid>eNp90MtOAjEUBuDGaATRjQ9gmrhBE7CXKTOzhPGakOgC1pPSnoaSuWA7A-HtLYIuXNjN6eLLf05-hK4pGdLwHhZq3Qwpjyk5QV0aR2wQJxE__f1z0UEX3q8IYXFEyTnqcEESnoxYF83HuJLOycZuADvYWNji2uCyLkC1hXS4BLWUlfUllpXGzRKcXEPbWIXBGFDNXitZVXJhta0L3M8mj3eX6MzIwsPVcfbQ_Plplr0Opu8vb9l4OlCRSMmAkoVMNZdGQswjJSPCOdeJSbkmsREUOBMQpaCpNkILpkYgmKQ6VknYPWK8h_qH3LWrP1vwTV5ar6AoZAV163MWDGcpESTQ2z90VbeuCtcFxRMiEjHiQd0flHK19w5Mvna2lG6XU5Lvy873ZeffZQd8c4xsFyXoX_rTbgD0ALa2gN0_Ufkk-5gdQr8AkTCItg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2638058563</pqid></control><display><type>article</type><title>A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)</title><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Peng, Jiangling ; Fan, Mingjie ; An, Chelsea ; Ni, Feng ; Huang, Wendong ; Luo, Jiankang</creator><creatorcontrib>Peng, Jiangling ; Fan, Mingjie ; An, Chelsea ; Ni, Feng ; Huang, Wendong ; Luo, Jiankang</creatorcontrib><description>Cannabidiol (CBD) is an abundant non‐psychoactive phytocannabinoid in cannabis extracts which has high affinity on a series of receptors, including Type 1 cannabinoid receptor (CB1), Type 2 cannabinoid receptor (CB2), GPR55, transient receptor potential vanilloid (TRPV) and peroxisome proliferator‐activated receptor gamma (PPARγ). By modulating the activities of these receptors, CBD exhibits multiple therapeutic effects, including neuroprotective, antiepileptic, anxiolytic, antipsychotic, anti‐inflammatory, analgesic and anticancer properties. CBD could also be applied to treat or prevent COVID‐19 and its complications. Here, we provide a narrative review of CBD's applications in human diseases: from mechanism of action to clinical trials.</description><identifier>ISSN: 1742-7835</identifier><identifier>EISSN: 1742-7843</identifier><identifier>DOI: 10.1111/bcpt.13710</identifier><identifier>PMID: 35083862</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Analgesics ; Anticancer properties ; Antipsychotics ; Cannabidiol ; Cannabinoid CB1 receptors ; Cannabinoid CB2 receptors ; cannabinoid receptor ; Cannabinoids ; Cannabis ; clinical trial ; Clinical trials ; Complications ; COVID-19 ; endocannabinoid system ; Inflammation ; Neuroprotection ; Peroxisome proliferator-activated receptors ; Receptors ; Transient receptor potential proteins</subject><ispartof>Basic & clinical pharmacology & toxicology, 2022-04, Vol.130 (4), p.439-456</ispartof><rights>2022 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley & Sons Ltd</rights><rights>2022 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4590-10ba9d3afae734ca40333d8f93d07f51e325e49ed1df5d52c6e52a1d7c8ffe623</citedby><cites>FETCH-LOGICAL-c4590-10ba9d3afae734ca40333d8f93d07f51e325e49ed1df5d52c6e52a1d7c8ffe623</cites><orcidid>0000-0003-3735-9466</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbcpt.13710$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbcpt.13710$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35083862$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peng, Jiangling</creatorcontrib><creatorcontrib>Fan, Mingjie</creatorcontrib><creatorcontrib>An, Chelsea</creatorcontrib><creatorcontrib>Ni, Feng</creatorcontrib><creatorcontrib>Huang, Wendong</creatorcontrib><creatorcontrib>Luo, Jiankang</creatorcontrib><title>A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)</title><title>Basic & clinical pharmacology & toxicology</title><addtitle>Basic Clin Pharmacol Toxicol</addtitle><description>Cannabidiol (CBD) is an abundant non‐psychoactive phytocannabinoid in cannabis extracts which has high affinity on a series of receptors, including Type 1 cannabinoid receptor (CB1), Type 2 cannabinoid receptor (CB2), GPR55, transient receptor potential vanilloid (TRPV) and peroxisome proliferator‐activated receptor gamma (PPARγ). By modulating the activities of these receptors, CBD exhibits multiple therapeutic effects, including neuroprotective, antiepileptic, anxiolytic, antipsychotic, anti‐inflammatory, analgesic and anticancer properties. CBD could also be applied to treat or prevent COVID‐19 and its complications. Here, we provide a narrative review of CBD's applications in human diseases: from mechanism of action to clinical trials.</description><subject>Analgesics</subject><subject>Anticancer properties</subject><subject>Antipsychotics</subject><subject>Cannabidiol</subject><subject>Cannabinoid CB1 receptors</subject><subject>Cannabinoid CB2 receptors</subject><subject>cannabinoid receptor</subject><subject>Cannabinoids</subject><subject>Cannabis</subject><subject>clinical trial</subject><subject>Clinical trials</subject><subject>Complications</subject><subject>COVID-19</subject><subject>endocannabinoid system</subject><subject>Inflammation</subject><subject>Neuroprotection</subject><subject>Peroxisome proliferator-activated receptors</subject><subject>Receptors</subject><subject>Transient receptor potential proteins</subject><issn>1742-7835</issn><issn>1742-7843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp90MtOAjEUBuDGaATRjQ9gmrhBE7CXKTOzhPGakOgC1pPSnoaSuWA7A-HtLYIuXNjN6eLLf05-hK4pGdLwHhZq3Qwpjyk5QV0aR2wQJxE__f1z0UEX3q8IYXFEyTnqcEESnoxYF83HuJLOycZuADvYWNji2uCyLkC1hXS4BLWUlfUllpXGzRKcXEPbWIXBGFDNXitZVXJhta0L3M8mj3eX6MzIwsPVcfbQ_Plplr0Opu8vb9l4OlCRSMmAkoVMNZdGQswjJSPCOdeJSbkmsREUOBMQpaCpNkILpkYgmKQ6VknYPWK8h_qH3LWrP1vwTV5ar6AoZAV163MWDGcpESTQ2z90VbeuCtcFxRMiEjHiQd0flHK19w5Mvna2lG6XU5Lvy873ZeffZQd8c4xsFyXoX_rTbgD0ALa2gN0_Ufkk-5gdQr8AkTCItg</recordid><startdate>202204</startdate><enddate>202204</enddate><creator>Peng, Jiangling</creator><creator>Fan, Mingjie</creator><creator>An, Chelsea</creator><creator>Ni, Feng</creator><creator>Huang, Wendong</creator><creator>Luo, Jiankang</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3735-9466</orcidid></search><sort><creationdate>202204</creationdate><title>A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)</title><author>Peng, Jiangling ; Fan, Mingjie ; An, Chelsea ; Ni, Feng ; Huang, Wendong ; Luo, Jiankang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4590-10ba9d3afae734ca40333d8f93d07f51e325e49ed1df5d52c6e52a1d7c8ffe623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analgesics</topic><topic>Anticancer properties</topic><topic>Antipsychotics</topic><topic>Cannabidiol</topic><topic>Cannabinoid CB1 receptors</topic><topic>Cannabinoid CB2 receptors</topic><topic>cannabinoid receptor</topic><topic>Cannabinoids</topic><topic>Cannabis</topic><topic>clinical trial</topic><topic>Clinical trials</topic><topic>Complications</topic><topic>COVID-19</topic><topic>endocannabinoid system</topic><topic>Inflammation</topic><topic>Neuroprotection</topic><topic>Peroxisome proliferator-activated receptors</topic><topic>Receptors</topic><topic>Transient receptor potential proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peng, Jiangling</creatorcontrib><creatorcontrib>Fan, Mingjie</creatorcontrib><creatorcontrib>An, Chelsea</creatorcontrib><creatorcontrib>Ni, Feng</creatorcontrib><creatorcontrib>Huang, Wendong</creatorcontrib><creatorcontrib>Luo, Jiankang</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Basic & clinical pharmacology & toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peng, Jiangling</au><au>Fan, Mingjie</au><au>An, Chelsea</au><au>Ni, Feng</au><au>Huang, Wendong</au><au>Luo, Jiankang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)</atitle><jtitle>Basic & clinical pharmacology & toxicology</jtitle><addtitle>Basic Clin Pharmacol Toxicol</addtitle><date>2022-04</date><risdate>2022</risdate><volume>130</volume><issue>4</issue><spage>439</spage><epage>456</epage><pages>439-456</pages><issn>1742-7835</issn><eissn>1742-7843</eissn><abstract>Cannabidiol (CBD) is an abundant non‐psychoactive phytocannabinoid in cannabis extracts which has high affinity on a series of receptors, including Type 1 cannabinoid receptor (CB1), Type 2 cannabinoid receptor (CB2), GPR55, transient receptor potential vanilloid (TRPV) and peroxisome proliferator‐activated receptor gamma (PPARγ). By modulating the activities of these receptors, CBD exhibits multiple therapeutic effects, including neuroprotective, antiepileptic, anxiolytic, antipsychotic, anti‐inflammatory, analgesic and anticancer properties. CBD could also be applied to treat or prevent COVID‐19 and its complications. Here, we provide a narrative review of CBD's applications in human diseases: from mechanism of action to clinical trials.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>35083862</pmid><doi>10.1111/bcpt.13710</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0003-3735-9466</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1742-7835 |
| ispartof | Basic & clinical pharmacology & toxicology, 2022-04, Vol.130 (4), p.439-456 |
| issn | 1742-7835 1742-7843 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2623329050 |
| source | Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
| subjects | Analgesics Anticancer properties Antipsychotics Cannabidiol Cannabinoid CB1 receptors Cannabinoid CB2 receptors cannabinoid receptor Cannabinoids Cannabis clinical trial Clinical trials Complications COVID-19 endocannabinoid system Inflammation Neuroprotection Peroxisome proliferator-activated receptors Receptors Transient receptor potential proteins |
| title | A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T05%3A47%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20narrative%20review%20of%20molecular%20mechanism%20and%20therapeutic%20effect%20of%20cannabidiol%20(CBD)&rft.jtitle=Basic%20&%20clinical%20pharmacology%20&%20toxicology&rft.au=Peng,%20Jiangling&rft.date=2022-04&rft.volume=130&rft.issue=4&rft.spage=439&rft.epage=456&rft.pages=439-456&rft.issn=1742-7835&rft.eissn=1742-7843&rft_id=info:doi/10.1111/bcpt.13710&rft_dat=%3Cproquest_cross%3E2638058563%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2638058563&rft_id=info:pmid/35083862&rfr_iscdi=true |